Clinic
Madera Community Hospital
Madera Community Hospital was paid $3.80M by Medicaid between Jan 2018 and Jan 2023, across 291 billing codes. Its largest line is 99199, Unlisted special service, procedure or report — 14% of everything it billed.
33Billing provider infoMADERA COMMUNITY HOSPITAL
MADERA, CA 93637
MADERA, CA 93637
33aNPI1669673646assigned 05/29/2007
33bProvider typeRural Health Clinic/Center
28Total paid$3.80M
24GClaims735,751
24DCodes billed291
24AFirst – last monthJan 2018 – Jan 2023
Compared with peers
Next to other Rural Health Clinic/Center providers in California
Rank by total paid#104 of 215
Median peer was paid$3.62M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official THOMPSON, TAMMY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 168,104 | $1.09M | |
| 2019 | 149,533 | $703K | |
| 2020 | 123,669 | $465K | |
| 2021 | 138,313 | $689K | |
| 2022 | 155,840 | $849K | |
| 2023 | 292 | $2K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99199 | Unlisted special service, procedure or report | 14% | 10,251 | 9,582 | $532K |
| 0450 | Emergency room services | 14% | 56,586 | 50,865 | $525K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 70,684 | 57,595 | $456K |
| Z7502 | 11% | 11,045 | 10,784 | $414K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 4.4% | 6,007 | 4,211 | $167K |
| 80053 | Comprehensive metabolic panel | 4.0% | 43,215 | 40,442 | $152K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 51,748 | 48,241 | $145K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.9% | 19,674 | 17,401 | $109K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 5,653 | 5,420 | $98K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.9% | 6,300 | 5,937 | $74K |
| Z7610 | 1.8% | 5,114 | 4,862 | $67K | |
| 59025 | Fetal non-stress test | 1.8% | 8,645 | 4,384 | $67K |
279 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 16,325 | $61K |
| 0360 | 1.5% | 2,774 | $58K | |
| Z7500 | 1.4% | 1,596 | $54K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 9,210 | $49K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.1% | 3,587 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,963 | $34K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,822 | $33K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,418 | $32K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,640 | $31K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,643 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,797 | $26K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,584 | $25K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,259 | $25K |
| 81025 | <1% | 14,317 | $23K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,142 | $22K |
| 81001 | <1% | 17,636 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,500 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,041 | $14K |
| 83690 | <1% | 7,634 | $13K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,091 | $13K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,763 | $12K |
| Z9725 | <1% | 284 | $12K | |
| 93000 | <1% | 2,008 | $12K | |
| 90686 | <1% | 1,949 | $12K | |
| 84484 | <1% | 4,600 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,131 | $11K |
| 0012A | <1% | 256 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,320 | $10K |
| 81003 | <1% | 12,429 | $9K | |
| 80061 | Lipid panel | <1% | 10,601 | $9K |
| 0710 | <1% | 2,094 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,534 | $8K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 1,167 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,444 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 425 | $8K |
| 47562 | <1% | 234 | $7K | |
| 0011A | <1% | 220 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,172 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,930 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,428 | $6K |
| 90732 | <1% | 296 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,734 | $5K |
| A4217 | Sterile water/saline, 500 ml | <1% | 2,740 | $5K |
| 0769 | <1% | 154 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,143 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,751 | $5K |
| 86318 | <1% | 1,888 | $5K | |
| 82948 | <1% | 5,076 | $5K | |
| 99283 | Emergency room visit (moderate) | <1% | 720 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,659 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,290 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 991 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,044 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,618 | $4K |
| 85730 | <1% | 3,160 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,276 | $4K |
| 90715 | <1% | 1,657 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,860 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,117 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,110 | $3K |
| 85610 | <1% | 4,152 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,056 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,915 | $3K |
| 83880 | <1% | 876 | $3K | |
| 76770 | <1% | 910 | $2K | |
| J3490 | Unclassified drugs | <1% | 13,776 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,287 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 1,495 | $2K |
| 73562 | <1% | 2,674 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,919 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,116 | $2K |
| 0270 | <1% | 10,566 | $2K | |
| 0002A | <1% | 49 | $2K | |
| 73030 | <1% | 1,715 | $2K | |
| 87276 | <1% | 1,272 | $2K | |
| 0403 | <1% | 23 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,162 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,825 | $2K |
| 0300 | <1% | 75 | $2K | |
| 85018 | <1% | 3,299 | $2K | |
| 76641 | <1% | 2,241 | $2K | |
| 90670 | <1% | 16 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,185 | $1K |
| 72110 | <1% | 1,661 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 637 | $1K |
| 83605 | <1% | 1,652 | $1K | |
| 94760 | <1% | 1,182 | $1K | |
| 73610 | <1% | 1,292 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 330 | $1K |
| 73130 | <1% | 1,135 | $1K | |
| 82962 | <1% | 2,218 | $1K | |
| 0761 | <1% | 1,496 | $1K | |
| 84439 | <1% | 3,396 | $1K | |
| 87275 | <1% | 1,272 | $1K | |
| 76801 | <1% | 487 | $1K | |
| 92558 | <1% | 773 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 66 | $1K |
| 83735 | <1% | 1,296 | $987.58 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 986 | $971.83 |
| 0001A | <1% | 57 | $965.58 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,615 | $946.24 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 39 | $945.00 |
| 77066 | Tomosynthesis, mammo | <1% | 1,360 | $937.29 |
| 82607 | <1% | 2,665 | $929.26 | |
| 92551 | <1% | 462 | $897.78 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,857 | $851.57 |
| 80074 | <1% | 797 | $841.63 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 410 | $815.16 |
| 73630 | <1% | 1,558 | $813.30 | |
| 87081 | <1% | 2,642 | $812.78 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,864 | $800.29 |
| V5008 | Hearing screening | <1% | 387 | $774.54 |
| 87040 | <1% | 583 | $748.21 | |
| 84702 | <1% | 2,799 | $740.68 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 532 | $734.17 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,316 | $703.10 |
| 71250 | <1% | 25 | $700.98 | |
| 73110 | <1% | 797 | $662.78 | |
| 94375 | <1% | 142 | $643.89 | |
| 80076 | <1% | 1,815 | $641.12 | |
| 72050 | <1% | 351 | $622.72 | |
| 87186 | <1% | 2,689 | $598.91 | |
| 86850 | <1% | 848 | $591.37 | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 528 | $571.57 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 36 | $557.50 |
| 86140 | <1% | 1,884 | $546.43 | |
| 90733 | <1% | 160 | $532.69 | |
| 73502 | <1% | 189 | $520.84 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 242 | $516.62 |
| 93971 | <1% | 248 | $505.95 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,281 | $501.71 |
| 86689 | <1% | 943 | $490.36 | |
| 71020 | <1% | 107 | $486.73 | |
| 82150 | <1% | 523 | $474.32 | |
| 87077 | <1% | 2,772 | $469.89 | |
| 86901 | <1% | 1,920 | $469.37 | |
| 94664 | <1% | 504 | $462.25 | |
| 99000 | <1% | 5,263 | $431.57 | |
| 82570 | <1% | 2,964 | $429.89 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 42 | $427.81 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 770 | $405.98 |
| 99070 | <1% | 422 | $397.07 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 388 | $395.28 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 60 | $372.20 |
| 0031A | <1% | 13 | $369.07 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 55 | $340.56 |
| 84436 | <1% | 754 | $338.50 | |
| 90674 | <1% | 92 | $337.81 | |
| 99421 | <1% | 61 | $330.60 | |
| 86900 | <1% | 1,614 | $323.92 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 969 | $320.14 |
| 86480 | <1% | 896 | $320.00 | |
| 81000 | <1% | 176 | $307.87 | |
| 84481 | <1% | 455 | $305.58 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 617 | $301.40 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 103 | $296.15 |
| 76536 | <1% | 574 | $292.36 | |
| 86592 | <1% | 1,431 | $286.01 | |
| 99201 | <1% | 12 | $284.76 | |
| 0324 | <1% | 26 | $275.44 | |
| 99422 | <1% | 12 | $272.16 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 225 | $265.95 |
| 84153 | <1% | 552 | $255.87 | |
| 86317 | <1% | 102 | $252.18 | |
| 82728 | <1% | 1,279 | $236.83 | |
| 82043 | <1% | 1,887 | $233.88 | |
| 90651 | <1% | 22 | $229.44 | |
| 86003 | <1% | 132 | $217.88 | |
| 87070 | <1% | 599 | $217.19 | |
| 87340 | <1% | 467 | $189.31 | |
| 87501 | <1% | 48 | $187.46 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 941 | $186.90 |
| 87338 | <1% | 628 | $180.88 | |
| 86038 | <1% | 283 | $180.71 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 201 | $180.00 |
| 86703 | <1% | 323 | $177.02 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 257 | $174.32 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 46 | $172.19 |
| 72100 | <1% | 178 | $171.16 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 63 | $170.92 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 787 | $161.08 |
| 83540 | <1% | 1,693 | $157.38 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 354 | $154.98 |
| 86235 | <1% | 280 | $145.90 | |
| 90658 | <1% | 1,177 | $141.99 | |
| 84100 | <1% | 200 | $138.14 | |
| 85379 | <1% | 234 | $132.00 | |
| 85651 | <1% | 2,186 | $128.83 | |
| 82746 | <1% | 455 | $119.25 | |
| 84550 | <1% | 1,162 | $113.79 | |
| 86580 | <1% | 493 | $111.01 | |
| 84466 | <1% | 813 | $104.41 | |
| 69209 | <1% | 60 | $101.52 | |
| 96376 | <1% | 356 | $99.24 | |
| 83615 | <1% | 401 | $97.81 | |
| 84703 | <1% | 696 | $86.77 | |
| 86431 | <1% | 530 | $75.30 | |
| 73080 | <1% | 126 | $74.54 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 193 | $74.52 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 82 | $73.73 |
| 82785 | <1% | 57 | $73.00 | |
| 86593 | <1% | 166 | $71.31 | |
| 0760 | <1% | 3,484 | $71.27 | |
| 84480 | <1% | 121 | $69.70 | |
| 86706 | <1% | 155 | $67.60 | |
| 82550 | <1% | 127 | $60.82 | |
| 80069 | <1% | 84 | $60.80 | |
| 82977 | <1% | 268 | $58.14 | |
| 80055 | <1% | 295 | $54.49 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 188 | $52.23 |
| 87280 | <1% | 151 | $51.45 | |
| 72072 | <1% | 114 | $49.37 | |
| 74019 | <1% | 13 | $45.97 | |
| 86331 | <1% | 179 | $45.90 | |
| 73140 | <1% | 107 | $45.62 | |
| 87147 | <1% | 444 | $45.50 | |
| 71010 | <1% | 71 | $44.67 | |
| 82274 | <1% | 38 | $42.42 | |
| 0250 | <1% | 148 | $41.86 | |
| 86171 | <1% | 91 | $39.92 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 100 | $39.88 |
| 74018 | <1% | 103 | $34.10 | |
| 82950 | <1% | 572 | $32.14 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 140 | $31.15 |
| 99443 | <1% | 38 | $30.78 | |
| 86039 | <1% | 290 | $30.24 | |
| 86701 | <1% | 68 | $28.34 | |
| 99173 | <1% | 250 | $27.88 | |
| J1815 | Injection, insulin, per 5 units | <1% | 198 | $26.35 |
| 86707 | <1% | 47 | $23.14 | |
| 82565 | <1% | 469 | $22.67 | |
| 87350 | <1% | 47 | $20.80 | |
| 86225 | <1% | 146 | $18.60 | |
| 82610 | <1% | 122 | $14.80 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 28 | $9.79 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 46 | $8.91 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 524 | $7.16 |
| 82272 | <1% | 12 | $6.11 | |
| 82248 | <1% | 530 | $6.08 | |
| 99050 | <1% | 219 | $5.55 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 811 | $4.94 |
| 99284 | Emergency room visit (serious) | <1% | 108 | $3.11 |
| 84156 | <1% | 153 | $2.93 | |
| 86695 | 0% | 12 | $0.00 | |
| 99441 | 0% | 397 | $0.00 | |
| 72040 | 0% | 96 | $0.00 | |
| 0250R | 0% | 97 | $0.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 116 | $0.00 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 0% | 16 | $0.00 |
| 86803 | 0% | 12 | $0.00 | |
| A6260 | Wound cleansers, any type, any size | 0% | 136 | $0.00 |
| 82952 | 0% | 13 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 43 | $0.00 |
| 82951 | 0% | 26 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 44 | $0.00 |
| 83001 | 0% | 16 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 34 | $0.00 |
| 86762 | 0% | 13 | $0.00 | |
| 77065 | Tomosynthesis, mammo | 0% | 72 | $0.00 |
| 90649 | 0% | 162 | $0.00 | |
| 0270R | 0% | 659 | $0.00 | |
| 82947 | 0% | 98 | $0.00 | |
| 84520 | 0% | 24 | $0.00 | |
| 96367 | 0% | 57 | $0.00 | |
| 82247 | 0% | 87 | $0.00 | |
| 90746 | 0% | 25 | $0.00 | |
| 99001 | 0% | 34 | $0.00 | |
| 0258R | 0% | 13 | $0.00 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 0% | 27 | $0.00 |
| 73590 | 0% | 28 | $0.00 | |
| 94060 | 0% | 12 | $0.00 | |
| 99442 | 0% | 28 | $0.00 | |
| 84145 | 0% | 12 | $0.00 | |
| 87177 | 0% | 41 | $0.00 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 12 | $0.00 |
| 86696 | 0% | 42 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 16 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMPSON, TAMMY (CFO)
Parent organizationMADERA FAMILY HEALTH SERVICES
| Provider | Location | Paid |
|---|---|---|
| Central Valley Specialty Hospital INC | Modesto, CA | $130.74M |
| Colusa Medical Center, LLC | Colusa, CA | $5.95M |
| Glenn Medical Center, LLC | Willows, CA | $5.62M |
| American Specialty Physicians Group INC | Modesto, CA | $5.11M |
| Colusa Medical Center, LLC | Williams, CA | $3.75M |
| Colusa Medical Center, LLC | Orland, CA | $2.44M |
| Colusa Medical Center LLC | Colusa, CA | $2.33M |
| Colusa Medical Center, LLC | Red Bluff, CA | $2.09M |
| Glenn Medical Center, LLC | Willows, CA | $1.73M |
| Colusa Medical Center, LLC | Arbuckle, CA | $1.37M |
| Coalinga Medical Center, LLC | Coalinga, CA | $1.32M |
| Glenn Medical Center, LLC | Willows, CA | $672K |
| Glenn Medical Center, LLC | Willows, CA | $669K |
| Progressive Specialty Therapy Services LLC | Modesto, CA | $404K |
| Progressive Home Health and Hospice Care, LLC | Modesto, CA | $389K |
| Coalinga Medical Center, LLC | Coalinga, CA | $254K |
| Glenn Medical Center, LLC | Willows, CA | $85K |
| Colusa Medical Center LLC | Colusa, CA | $51K |
| 1125 Sir Francis Drake Boulevard Operating Company, LLC | Kentfield, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.